Can TROP2 be used as a prognostic marker in endometrioid endometrial carcinoma?
| Autor: | Celik SY; Department of Pathology, Faculty of Medicine, Sıtkı Kocman University, Muğla, Turkey., Çelik Öİ; Department of Pathology, Faculty of Medicine, Sıtkı Kocman University, Muğla, Turkey. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Indian journal of pathology & microbiology [Indian J Pathol Microbiol] 2020 Jul-Sep; Vol. 63 (3), pp. 418-422. |
| DOI: | 10.4103/IJPM.IJPM_783_19 |
| Abstrakt: | Background: Endometrioid-type endometrial carcinoma is the most common malignancy of the female genital tract in developed countries. The prognosis greatly depends on the grade and stage of the disease. Aims: In some patients, the disease recurs in a short time after the surgical/medical therapy. Hence, it is important to predict the patients who will have worse prognosis at the beginning, to choose the appropriate treatment; resuming the search of new prognostic markers. Therefore, our study aimed to detect trophoblast cell surface antigen 2 (TROP2) as a new prognostic marker. Settings and Design: The patients who underwent a hysterectomy and diagnosed with endometrioid-type endometrial carcinoma were evaluated retrospectively and TROP2 immunostain was performed to their tumoral slides. Materials and Methods: We evaluated TROP2 expressions in 102 patients immunohistochemically who underwent hysterectomy with the diagnosis of endometrioid-type endometrial carcinoma histopathologically and correlated them with the other generally accepted prognostic parameters. Statistical Analysis: The Kolmogorov-Smirnov test and Q-Q plot test were used to verify the normality of the distribution of continuous variables. The Chi-square/Fisher's exact tests were used for categorical variables. Analyses were performed with SPSS Statistics for Windows, Version 20. Results: High overexpression of TROP2 was seen in larger, higher-grade, deeper-invasive tumors, tumors with vascular invasion, and pelvic-lymph-node metastasis. These results were statistically significant (P ≤ 0.05). Conclusion: Overexpression of TROP2 in endometrioid-type endometrial carcinoma seems to be a poor prognostic factor; it may be useful in determining the biologically more aggressive tumors before the treatment. This early determination is very important to choose the appropriate surgery, adjuvant-treatments, and follow-up. Competing Interests: None |
| Databáze: | MEDLINE |
| Externí odkaz: |
|